Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate

Drug Development and Industrial Pharmacy

Volumn 37, Issue 11, 2011, Pages 1357-1364

  Zhang, Zhi Liang ^a   Le, Yuan ^a   Wang, Jie Xin ^a   Chen, Jian Feng ^a  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

Author keywords

Crystallization; Dissolution rate; Irbesartan; Micron sized particles; Poorly water soluble drug

Indexed keywords

HYDROXYPROPYLMETHYLCELLULOSE; IRBESARTAN; POLOXAMER; POLYSORBATE 80; POVIDONE;

ARTICLE; CHEMICAL COMPOSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TRANSFORMATION; FREEZE DRYING; IN VITRO STUDY; INFRARED SPECTROSCOPY; LIQUID; PARTICLE SIZE; PRECIPITATION; PRESSURE; SCANNING ELECTRON MICROSCOPY; SUSPENSION; X RAY DIFFRACTION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; FREEZE DRYING; PARTICLE SIZE; SOLUBILITY; TETRAZOLES; X-RAY DIFFRACTION;

EID: 80053948143     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.575379     Document Type: Article

References (26)

1. Lipinski C. (2002). Poor aqueous solubility, an industry wide problem in drug discovery. Am Pharm Rev, 5:82-85.
2. Rasenack N, Müller BW. (2002). Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm Res, 19:1894-1900. (Pubitemid 36016039)
3. Müler RH, Peters K. (1998). Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique. Int J Pharm, 160:229-237. (Pubitemid 28083096)
4. Rabinow BE. (2004). Nanosuspensions in drug delivery. Nat Rev Drug Discov, 3:785-796. (Pubitemid 39242830)
5. Matteucci ME, Hotze MA, Johnston KP, Williams RO 3rd. (2006). Drug nanoparticles by antisolvent precipitation: Mixing energy versus surfactant stabilization. Langmuir, 22:8951-8959. (Pubitemid 44626160)
6. Chen X, Matteucci ME, Lo CY, Johnston KP, Williams RO 3rd. (2009). Flocculation of polymer stabilized nanocrystal suspensions to produce redispersible powders. Drug Dev Ind Pharm, 35:283-296.
7. Yassin AE, Alanazi FK, El-Badry M, Alsarra IA, Barakat NS, Alanazi FK. (2009). Preparation and characterization of spironolactoneloaded gelucire microparticles using spray-drying technique. Drug Dev Ind Pharm, 35:297-304.
8. Pouleur HG. (1997). Clinical overview of irbesartan: A new angiotensin II receptor antagonist. Am J Hypertens, 10:318S-324S. (Pubitemid 28133256)
9. Brunner HR. (1997). The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens, 10:311S-317S. (Pubitemid 28133255)
10. Chawla G, Bansal AK. (2008). Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and nonpolymeric hydrophilic additives. Acta Pharm, 58:257-274.
11. Wang Z, Huang Q, Wang J, Shao L, Chen J. (2008). Preparation of amorphous micronized irbesartan by an antisolvent precipitation method. J Beijing Univ Chem Tech, 35:69-73.
12. Hirlekar R, Kadam V. (2009). Preformulation study of the inclusion complex irbesartan-β-cyclodextrin. AAPS Pharmscitech, 10:276-281.
13. Hancock BC, Parks M. (2000). What is the true solubility advantage for amorphous pharmaceuticals?. Pharm Res, 17:397-404. (Pubitemid 30395293)
14. Pan X, Julian T, Augsburger L. (2008). Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: A case study with indomethacin [correction of indomethicin]. Drug Dev Ind Pharm, 34:221-231. (Pubitemid 351317152)
15. de Waard H, Hinrichs WL, Frijlink HW. (2008). A novel bottom-up process to produce drug nanocrystals: Controlled crystallization during freeze-drying. J Control Release, 128:179-183.
16. Hancock BC, Zografi G. (1994). The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res, 11:471-477. (Pubitemid 24144434)
17. Chan HK, Chew NY. (2003). Novel alternative methods for the delivery of drugs for the treatment of asthma. Adv Drug Deliv Rev, 55:793-805. (Pubitemid 36776794)
18. Caron A, Chantreux D, Bouloumie C. (1997). Process for the preparation of a tetrazole derivative in two crystalline forms and novel the crystalline forms thereof. US patent no. 5629331.
19. Reddy RB, Sudhakar S. (2003). Amorphous form of 2-n-butyl-3-((2-(1h- tetrazol-5-yl) (1,1β-biphenyl)-4-yl) methyl)-1,3-diazaspiro (4,4β) non-1-en-4-one. World patent no. 03050110.
20. Parthasaradhi RB, Rathnakar RK, Raji RR, Ramakrishna RM. (2004). A novel crystalline form of irbesartan. World patent no. 2004089938.
21. Ziller KH, Rupprecht HH. (1990). Control of crystal growth in drug suspensions. Part II: Influence of polymers on dissolution and crystallization during temperature cycling. Pharm Ind, 52:1017-1022. (Pubitemid 20330148)
22. Muhammad SA, Langrish T, Tang P, Adi H, Chan HK, Kazarian SG et al. (2010). A novel method for the production of crystalline micronised particles. Int J Pharm, 388:114-122.
23. Lu J, Wang X, Ching C. (2003). Effect of additives on the crystallization of lysozyme and chymotrypsinogen A. Crystal Growth & Design, 3:83-87. (Pubitemid 37130465)
24. Zhang ZB, Shen ZG, Wang JX, Zhang HX, Zhao H, Chen JF et al. (2009). Micronization of silybin by the emulsion solvent diffusion method. Int J Pharm, 376:116-122.
25. Williams ML, Landel RF, Ferry JD. (1955). The temperature dependence of relaxation mechanisms in amorphous polymers and other glass-forming liquids. J Am Chem Soc, 77:3701-3707.
26. Lang R, Winter G, Vogt L, Zurcher A, Dorigo B, Schimmele B. (2009). Rational design of a stable, freeze-dried virus-like particle-based vaccine formulation. Drug Dev Ind Pharm, 35:83-97.